Outcome after Neuro-interventional Treatment of Intracranial Aneurysm (as a First Treatment Modality).

Q4 Biochemistry, Genetics and Molecular Biology
Hossein Ghanaati, Aryoobarzan Rahmatian, Mohammad Reza Amiri-Nikpour, Davar Altafi, Morteza Taheri, Seyed Bahaadin Siroos, Madjid Shakiba, Reza Elahi, Mahsa Alborzi Avanaki
{"title":"Outcome after Neuro-interventional Treatment of Intracranial Aneurysm (as a First Treatment Modality).","authors":"Hossein Ghanaati, Aryoobarzan Rahmatian, Mohammad Reza Amiri-Nikpour, Davar Altafi, Morteza Taheri, Seyed Bahaadin Siroos, Madjid Shakiba, Reza Elahi, Mahsa Alborzi Avanaki","doi":"10.14712/23362936.2024.2","DOIUrl":null,"url":null,"abstract":"<p><p>Endovascular treatment is widely applied as the first-line treatment for intracranial aneurysms and includes simple coiling (SC), stent-assisted coiling (SAC), flow diversion stent, and flow disruption stent. The present study is a retrospective cohort study performed in Imam Khomeini Hospital, Department of Neurovascular Intervention, between March 2016 and March 2021. A total number of 229 patients with intracranial aneurysms who underwent therapeutic intravascular interventions were enrolled, of which 89 were treated with SC, 111 with SAC, 25 with flow diversion stent, and 4 with flow disruption stent. The mean age of the subjects was 51.8±12.6 years, and 51.1% were male. Modified Raymond-Roy classification (MRRC) was used to define the occlusion outcome. The success rate, considered as Class I and Class II of MRRC at treatment time was 89% (94.4% in SC, and 84.7% in SAC), which was increased to 90.9% (94% in SC, 93% in SAC, 69.6% in flow diversion stenting, 100% in flow disruption) at 6-month follow-up, and 84.6% (80.8% in SC, 87.8% in SAC, 78.3% in flow diversion stenting, and 100% in flow disruption) at 12-month follow-up. The mean modified Rankin Scale (mRS) before the procedure was 0.05±0.26 which was increased to 0.22±0.76 after the procedure, 0.22±0.76 at 6 months, and 0.30±0.95 at 12 months (P&lt;0.001). Similar to previous studies, the present study demonstrates that neurovascular intervention can treat ruptured aneurysms as the first therapeutic modality with favourable outcomes. A double-blind, randomized clinical trial is needed to eliminate the confounding factors and better demonstrate the outcome.</p>","PeriodicalId":35490,"journal":{"name":"Prague medical report","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prague medical report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14712/23362936.2024.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Endovascular treatment is widely applied as the first-line treatment for intracranial aneurysms and includes simple coiling (SC), stent-assisted coiling (SAC), flow diversion stent, and flow disruption stent. The present study is a retrospective cohort study performed in Imam Khomeini Hospital, Department of Neurovascular Intervention, between March 2016 and March 2021. A total number of 229 patients with intracranial aneurysms who underwent therapeutic intravascular interventions were enrolled, of which 89 were treated with SC, 111 with SAC, 25 with flow diversion stent, and 4 with flow disruption stent. The mean age of the subjects was 51.8±12.6 years, and 51.1% were male. Modified Raymond-Roy classification (MRRC) was used to define the occlusion outcome. The success rate, considered as Class I and Class II of MRRC at treatment time was 89% (94.4% in SC, and 84.7% in SAC), which was increased to 90.9% (94% in SC, 93% in SAC, 69.6% in flow diversion stenting, 100% in flow disruption) at 6-month follow-up, and 84.6% (80.8% in SC, 87.8% in SAC, 78.3% in flow diversion stenting, and 100% in flow disruption) at 12-month follow-up. The mean modified Rankin Scale (mRS) before the procedure was 0.05±0.26 which was increased to 0.22±0.76 after the procedure, 0.22±0.76 at 6 months, and 0.30±0.95 at 12 months (P<0.001). Similar to previous studies, the present study demonstrates that neurovascular intervention can treat ruptured aneurysms as the first therapeutic modality with favourable outcomes. A double-blind, randomized clinical trial is needed to eliminate the confounding factors and better demonstrate the outcome.

颅内动脉瘤神经介入治疗(作为第一种治疗方式)后的效果。
血管内治疗作为颅内动脉瘤的一线治疗方法被广泛应用,包括简单卷曲(SC)、支架辅助卷曲(SAC)、血流分流支架和血流阻断支架。本研究是一项回顾性队列研究,于 2016 年 3 月至 2021 年 3 月期间在伊玛目霍梅尼医院神经血管介入科进行。共有 229 名颅内动脉瘤患者接受了治疗性血管内介入治疗,其中 89 人接受了 SC 治疗,111 人接受了 SAC 治疗,25 人接受了血流分流支架治疗,4 人接受了血流中断支架治疗。受试者的平均年龄为(51.8±12.6)岁,51.1%为男性。改良雷蒙德-罗伊分级(MRRC)用于定义闭塞结果。治疗时MRRC I级和II级的成功率为89%(SC为94.4%,SAC为84.7%),随访6个月时成功率增至90.9%(SC为94%,SAC为93%,血流分流支架植入术为69.6%,血流阻断术为100%),随访12个月时成功率增至84.6%(SC为80.8%,SAC为87.8%,血流分流支架植入术为78.3%,血流阻断术为100%)。术前平均改良 Rankin 量表(mRS)为 0.05±0.26,术后增至 0.22±0.76,6 个月时为 0.22±0.76,12 个月时为 0.30±0.95(P<0.001)。与之前的研究相似,本研究表明,神经血管介入治疗可作为治疗动脉瘤破裂的第一种治疗方式,且疗效良好。需要进行双盲、随机临床试验,以消除混杂因素,更好地证明疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Prague medical report
Prague medical report Medicine-Medicine (all)
CiteScore
1.10
自引率
0.00%
发文量
19
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信